San Carlos, Calif. • 650-508-2116 • www.neurogesx.com
Exchange and Ticker: Nasdaq: NGSX
Filing Range: 4.00M shares @ $13.00 to $15.00
Offering Price: $11.00
Close on First Day: $10.65
Offering Size: $44.00M
Shares Outstanding: 12,487,898M
Underwriter: Morgan Stanley
Co-managers: Pacific Growth Equities Inc./ Lazard Capital Markets/ Susquehanna Financial Group
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Davis Polk & Wardwell
Auditor: Ernst & Young LLP
Market Capitalization on 5/31/07: $101.15M
Close price at current month end: $8.10
DESCRIPTION
Develops and commercializes treatments for nerve signaling disorders. The company also develops and produces pharmaceuticals for intractable pain relief. NeurogesX’s initial products are focused on the treatment of chronic pain in the areas of postherpetic neuralgia (PHN), painful HIV-associated sensory neuropathy (HIV-AN) and painful diabetic neuropathy (PDN). Competitors include Lidoderm, Endo Pharmaceuticals, Pfizer, GlaxoSmithKline, Merck & Co., Novartis AG and Eli Lilly.
VENTURE BACKERS
Alta Partners, ARCH Venture Partners, Diamond Capital Company, Life Science Ventures, Mitsubishi International Corp., Montreux Equity Partners, Teachers Insurance & Annuity Association College Retirement, Walden International.
Source: Thomson Financial